Patent Application
20190284532
The present invention relates to novel feeder cells into which a costimulatory molecule is introduced, and a method of mass-proliferating high purity gamma-delta (γδ) T cells in vitro using the same in the presence of a low concentration of IL-2 without T cell receptor stimulation.
Recently, significant processes for understanding the role of human γδ T cells have been made in immune responses against infections, tumors and autoimmune diseases. Human γδ T cells expressing Vγ9Vδ2 TCR have been known as the major subset which can be activated in peripheral blood in a human leukocyte antigen (HLA)-unrestricted manner by small non-peptidic phosphoantigens. Vγ9Vδ2 T cells include NKG2D and ULBP4, which are expressed in tumor cells, and are capable of recognizing their ligands, thereby exhibiting strong cytotoxicity against tumor cells. In addition, both manipulations of the activation of Vγ9Vδ2 T cells in vivo and the activation of autologous Vγ9Vδ2 T cells expanded ex vivo and adoptively transferred are being considered as new immunotherapeutic approaches. Many protocols for the ex vivo expansion of Vγ9Vδ2 T cells using a natural antigen, i. e., isopentenyl pyrophosphate, against human Vγ9Vδ2 T cells have been developed. Particularly, Correia et al. have reported that a phosphoantigen alone cannot activate Vγ9Vδ2 T cells, and the addition of a high concentration of IL-2 is significant for completing the activation of Vγ9Vδ2 T cells. More significantly, mature dendritic cells pretreated with aminobisphosphate are able to induce the expansion of high-purity Vγ9Vδ2 T cells in peripheral blood mononuclear cells (PBMCs), which does not correspond to a conventional culture protocol. Since the mature dendritic cells express a variety of costimulatory molecules, including CD80, CD83 and 4-1BBL, data on these molecules shows that signaling using a large number of costimulatory receptors activates Vγ9Vδ2 T cells. Even though it has been proven that various costimulatory molecules including CD80 and a 4-1BB ligand (4-1BBL) participate in promotion of the proliferation and survival of peripheral Vγ9Vδ2 T cells, the functions of CD83 and its ligand for the activation of γδ T cells are little known.
An object of the present invention is directed to providing feeder cells that are able to express a costimulatory molecule group and stimulate γδ T cells.
Another object of the present invention is also directed to providing a composition and method for proliferating high purity γδ T cells in vitro using the feeder cells in the presence of a low concentration of IL-2 without T cell receptor stimulation.
To attain the objects of the present invention, the present invention provides feeder cells for stimulating γδ T cells, which express a costimulatory molecule group including 4-1BBL, CD80 and CD83, but do not express HLA.
The present invention provides a composition for in vitro proliferating γδ T cells including the feeder cells for stimulating γδ T cells.
The present invention also provides a method of in vitro proliferating γδ T cells, which includes ex vivo co-culturing the feeder cells for stimulating γδ T cells and γδ T cells without T cell receptor stimulation.
According to the present invention, high purity γδ T cells can be mass-proliferated in vitro by stimulating γδ T cells using feeder cells in the presence of a low concentration of IL-2 without T cell receptor stimulation, and the γδ T cells can differentiate into central memory cells and have cytolytic activity against tumor cells.
The inventors investigated the roles of costimulatory molecules including CD83 for the survival, proliferation and cytokine formation of human γδ T cells in vitro. First, since K562 cells do not express HLA molecules, but have an advantage of expressing adhesion molecules, for example, ICAM, LFA-3 and NKG2D ligands and MHC class I-related chain A, a stable K562-based transformant expressing a costimulatory molecule group consisting of 4-1BBL/CD80/CD83 or a costimulatory molecule group consisting of 4-1BBL/CD80/CD83/CD40L was prepared. These transformants were further transduced to raise the expression rate(s) of Fc receptor(s) such as CD32 and/or CD64.
It has been known that the 4-1BB/4-1BBL interaction is independent from B7/CD28 signaling, and increases the survival of cells activated in vivo. Particularly, the participation of CD83 noticeably upregulated during the maturation of dendritic cells has been known to inhibit apoptosis, thereby improving the long-term survival of T cells.
In addition, stimulation may be performed by additionally transferring costimulatory molecules such as γδ T cell-stimulatory molecules, i.e., MIC and ULBP to the cells. The inventors confirmed that K562-based feeder cells allow the long-term growth of functional effector-memory Vγ9Vδ2 T cells, and the proliferation rate of high purity Vγ9Vδ2 T cells is increased in vitro in the presence of a low concentration of IL-2 without T cell receptor stimulation.
From the above-described result, it was found that the costimulatory signals involved in the activation and survival of human γδ T cells eventually improve γδ T cell-based immunotherapeutic strategies for cancer, infections and autoimmune diseases.
Therefore, the present invention relates to feeder cells for stimulating γδ T cells, which express a costimulatory molecule group including 4-1BBL, CD80 and CD83 and do not express HLA.
The term “feeder cell” used herein refers to artificially manufactured antigen-presenting cells, and non-immune cells modified to express an immune molecule. Feeder cells expressing an MHC class I or II (MHC I or II) molecule alone or in combination with other accessory molecules (costimulatory molecules and/or adhesion molecules) may be used to study various aspects of T cell-activating cells which can be easily cultured, such as tumor cells or a fibroblast cell line in vivo. For the purpose of the present invention, the feeder cell means a cell in which cDNA of costimulatory molecules is introduced into any one of human cells without HLA expressing capacity, such as K562 cells and recombinant HEK 293T cells from which an HLA gene is artificially removed, but the present invention is not limited thereto.
The feeder cells of the present invention are prepared from cells without an HLA expressing capacity, and prepared by introducing respective nucleic acids encoding a costimulatory molecule group including costimulatory molecules such as 4-1BBL, CD80 and CD83, or a costimulatory molecule group including 4-1BBL, CD80, CD83 and CD40L into cells having no HLA expressing capacity or from which HLA expressing capacity is removed. Compared with conventional feeder cells, the feeder cells of the present invention are able to stimulate cells without the stimulation with an immunostimulatory ligand, that is, a T cell receptor.
Therefore, the feeder cells may mass-produce high purity γδ T cells in vitro only with the combination of costimulatory molecules without T cell receptor stimulation.
In the feeder cells, Fc receptor(s), that is, CD32 and/or CD64, other than the costimulatory molecules, are/is further transduced to increase the expression rate(s) of CD32 and/or CD64.
The feeder cells may stimulate any one type of naive γδ T cells isolated from human PBMCs and enriched γδ T cells obtained by stimulating human PBMCs with zoledronic acid.
The naive γδ T cells may be isolated from human PBMCs by FACS sorting or using anti-γδ antibody-conjugated microspheres, thereby exhibiting Vγ9Vδ2 subsets and having CD83/4-1BBL/anti-CD28 signals.
The enriched γδ T cells may be obtained by stimulating human PBMCs with zoledronic acid, or by being isolated by FACS sorting or using anti-γδ antibody-conjugated microspheres after stimulation with zoledronic acid. The enriched γδ T cells may exhibit Vγ9Vδ2 subsets the same as the naive γδ T cells, and have CD83/4-1BBL/anti-CD28 signals.
To provide antigenic specificity, the feeder cells of the present invention may be further transduced with nucleic acid(s) encoding any one or more antigens selected from the group consisting of a tumor antigen, a pathogenic antigen and an autoantibody.
The term “antigen” used herein is well known in the art, and includes an epitope, a peptide fragment of an antigen capable of binding to an MHC molecule, and an immunogen, as well as all molecules capable of binding to an antibody. In the present invention, as an antigen, a tumor antigen, a pathogenic antigen or an autoantibody (normal or pathological) may be used, but the present invention is not limited thereto.
The tumor antigen refers to a tumor-associated antigen (TAA), which is an antigen associated with a tumor. Examples of well-known TAAs include ovalbumin, survivin, gp75, gp1OO, MDM2, MART-1, MAGE-1, MAGE-3, tyrosinase, telomerase, her-2/neu, α-1 fetoprotein, G250, and NY-ESO-1. Partial peptide fragment sequences of TAAs binding to an MHC molecule include Ova257 (SIINFEKL; SEQ ID NO: 25), tyrosinase-related protein 1455 (Trp1455; TAPDNLGYA; SEQ ID NO: 26), Trp2180 (SVYDFFVWL; SEQ ID NO: 27), gp10025 (gp10025; EGSRNQDWL; SEQ ID NO: 28), a MAGE 1 nonapeptide (EADPTGHSY; SEQ ID NO: 29), a MART-APL peptide (LAGIGILTV; SEQ ID NO: 30), a natural peptide (AAGIGILTV; SEQ ID NO: 31), and a PSA-1 peptide (FLTPKKLQCV; SEQ ID NO: 32). The sequences of additional tumor-associated peptides and antigens are known to those of ordinary skill in the art.
The pathogenic antigen refers to an organism or virus that causes a disease, or an attenuated derivative thereof. The term “pathogen” refers to any virus or organism, or an attenuated derivative thereof, which is involved in the occurrence of a disease. The pathogens may include bacterial, protozoan, fungal and viral pathogens, for example, Helicobacters such as Helicobacter pylori, Salmonella sp., Shigella sp., Enterobacter sp., and Campylobacter sp., various mycobacteria such as Mycobacterium leprae and Mycobacterium tuberculosis, Bacillus anthracis, Yersinia pestis, Francisella tularensis, Brucella sp., Leptospira interrogans, Staphylococcus sp. such as S. aureus, Streptococcus sp., Clostridum sp., Candida albicans, Plasmodium sp., Leishmania sp., Trypanosoma sp., human immunodeficient virus (HIV), hepatitis C virus (HCV), human papilloma virus (HPV), cytomegalovirus (CMV), HTLV, herpes viruses (e.g., Type 1 herpes simplex virus, Type 2 herpes simplex virus, Corona virus, Varicella-Joster virus, and Epstein-Barr virus), papilloma virus, influenza virus, hepatitis B virus, poliovirus, measles virus, mumps virus, and rubella virus, but the present invention is not limited thereto.
The autoantibody is an antinuclear antibody, an anti-γ globulin antibody, an antibody against a self-hemocyte component or an antibody against a self-organ, but the present invention is not particularly limited thereto. When the autoantibody is used as a foreign antigen, a CD4 T cell vaccine may induce potent antitumor immunity, and thus may be effective for overcoming potential immune tolerance to an auto-antigen expressed in normal tissue.
The term “costimulatory molecule” used herein is a material participating in the interaction between a receptor-ligand pair expressed on the surface of an antigen-presenting cell and a T cell, and to induce the expression and proliferation of a cytokine gene, two or more signals are required for resting T cells. A first signal is a signal imparting specificity, generated by the interaction between an MHC/peptide complex and a TCR/CD3 complex, and a second signal is antigen-nonspecific, and called a “costimulatory” signal. These signals are known to have activity provided by bone marrow-derived helper cells such as macrophages and dendritic cells. The costimulatory molecule performs complete activation of γδ T cells by mediating a costimulatory signal required under a normal physiological condition. In the present invention, as such costimulatory ligands, a combination of 4-1BBL, CD80 and CD83 or a combination of 4-1BBL, CD80, CD83 and CD40L is used.
The feeder cells of the present invention may be prepared by transducing costimulatory molecules into human cells without HLA expressing capacity or from which HLA expressing capacity is removed using a known transformation technique. According to an exemplary embodiment of the present invention, costimulatory molecules may be transduced into K562 cells.
A nucleic acid encoding the costimulatory molecule may be DNA or RNA.
Preferably, 4-1BBL may be a human or mouse-derived nucleic acid sequence, for example, a base sequence set forth in SEQ ID NO: 1, but the present invention is not limited thereto.
CD80 may be a human or mouse-derived nucleic acid sequence. For example, CD80 may be a base sequence set forth in SEQ ID NO: 2, but the present invention is not particularly limited thereto.
CD83 may be a human or mouse-derived nucleic acid sequence, for example, a base sequence set forth in SEQ ID NO: 3, but the present invention is not particularly limited thereto.
CD40L may be a human or mouse-derived nucleic acid sequence, for example, a base sequence set forth in SEQ ID NO: 4, but the present invention is not particularly limited thereto.
When DNA is selected as a nucleic acid encoding the costimulatory molecule, it may be provided to human cells which have no HLA expressing capacity or from which HLA expressing capacity is removed in a form of being inserted into a vector.
The term “vector” used herein means a nucleic acid molecule capable of delivering a different nucleic acid linked to the nucleic acid itself. There is a type of vector, called “plasmid,” which is a circular double-stranded DNA loop capable of ligating an additional DNA segment. Another type of vector is a viral vector capable of ligating an additional DNA segment with a viral genome. Some vectors can be self-replicated in a host cell when being introduced into the host cell (e.g., a bacterial vector having a bacterial origin of replication and an episomal vector for a mammal). When being introduced into a host cell, a different vector (e.g., a non-episomal vector for a mammal) is able to be integrated into the genome of the host cell, and replicated with the host genome. In addition, some vectors may direct the expression of genes operably linked to each other. The vector of the specification refers to “recombinant expression vector” (or simply called “expression vector”). Generally, since an expression vector useful for a recombinant DNA technique is typically the most commonly-used vector type, the “plasmid” and “vector” may be used interchangeably. However, the present invention may include different types of expression vectors such as viral vectors providing equivalent functions (e.g., an adenovirus vector, an adeno-associated virus (AAV) vector, a herpes virus vector, a retrovirus vector, a lentivirus vector, and a baculovirus vector), and preferably, a retroviral vector.
The retrovirus is an RNA virus having a different life cycle from a lytic virus. In this regard, the retrovirus is an infectious agent that replicates through a DNA intermediate. When cells are infected by the retrovirus, the viral genome is converted into DNA due to reverse transcriptase. A DNA copy is used as a template for producing an encoded viral protein, which is necessary for a new RNA genome and the assembly of an infectious viral particle. There are many types of retroviruses, including all different families of retroviruses, for example, murine leukemia virus (MLV), human immunodeficiency virus (HIV), equine infectious anemia virus (EIAV), mouse mammary tumor-like virus (MMTV), Rouse sarcoma virus (RSV), Fujinami sarcoma virus (FuSV), Moloney murine leukemia virus (Mo-MLV), FBR murine osteosarcoma virus (FBR MSV), Moloney murine sarcoma virus (Mo-MSV), Abelson murine leukemia virus (A-MLV), avian myeloblastosis virus-29 (MC29), avian erythromblastasis virus (AEV) and lentivirus. Detailed lists of the retroviruses are shown in Coffin et al. (“Retroviruses” 1997 Cold Spring Harbour Laboratory Press Eds: J M Coffin, S M Hughes, H E Varmus pp 758-763).
Transformation includes any method for introducing a nucleic acid into an organism, a cell, tissue or an organ, and may be carried out by selecting a suitable standard technique according to host cells as known in the art. Such methods include electroporation, plasma fusion, calcium phosphate (CaPO4) precipitation, calcium chloride (CaCl2) precipitation, stirring with silicon carbide fibers, agrobacteria-mediated transformation, PEG, dextran sulfate, and Lipofectamine, but the present invention is not limited thereto.
According to an exemplary embodiment of the present invention, each cDNA of each of the genes of human costimulatory molecules 4-1BBL, CD80, CD83 and CD40L is prepared through PCR amplification, and inserted into a retrovirus vector. The pcDNA3/CD80, pLXSN/4-1BBL, pcDNA3/CD83, and pcDNA3/CD40L are sequentially introduced into K562 cells for transformation.
The term “gamma-delta T cells” used herein may be used interchangeably with “γδ T cells.”
The present invention also relates to a composition for in vitro proliferating γδ T cells including feeder cells for stimulating the γδ T cells.
The present invention also relates to a method of in vitro proliferating γδ T cells, which includes ex vivo co-culturing feeder cells for stimulating γδ T cells and γδ T cells without T cell receptor stimulation.
The γδ T cells used in the method of in vitro proliferating the γδ T cells according to the present invention may be any one of naive γδ T cells isolated from human PBMCs or enriched γδ T cells obtained by stimulating human PBMCs with zoledronic acid.
The co-culture of feeder cells and γδ T cells may be carried out without T cell receptor stimulation.
At this time, the T cell receptor stimulation means culturing in the presence of an anti-CD3 antibody or anti-γδ TCR antibody.
Therefore, the co-culture of feeder cells and γδ T cells are performed in a cell culture medium containing a low concentration of IL-2 in the absence of the anti-CD3 antibody or anti-γδ TCR antibody.
The cell culture medium may be a complete medium for animal cell culture. For example, Dulbecco's Modified Eagle's Medium (DMEM), Minimal Essential Medium (MEM), Basal Medium Eagle (BME), RPMI1640, F-10, F-12, α-Minimal Essential Medium (αMEM), Glasgow's Minimal Essential Medium (GMEM), or Iscove's Modified Dulbecco's Medium may be used, but the present invention is not limited thereto.
IL-2 may be added at a concentration of 20 to 100 IU/mL. Compared with a conventional method of in vitro proliferating γδ T cells, performed at a high concentration of 300 IU/mL or more, the method according to the present invention is performed with a considerably lower concentration of IL-2.
According to an exemplary embodiment of the present invention, the in vitro proliferation of γδ T cells may be performed by co-culturing feeder cells for stimulating γδ T cells, expressing a costimulatory molecule group consisting of 4-1BBL, CD80, CD83 and CD40L, and naive γδ T cells or enriched γδ T cells in the presence of 20 to 100 IU/mL of IL-2 without an anti-CD3 antibody or anti-γδ TCR antibody, or feeder cells for stimulating γδ T cells, expressing a costimulatory molecule group consisting of 4-1BBL, CD80 and CD83 and naive γδ T cells or enriched γδ T cells in the presence of 20 to 100 IU/mL of IL-2 without the anti-CD3 antibody or anti-γδ TCR antibody.
The simulation with feeder cells is repeated at intervals of 7 to 10 days, and the in vitro culture is able to be performed for 90 days or more, and more preferably, 14 to 100 days. Considering that the conventional method of in vitro proliferating γδ T cells is performed within a maximum of 14 days, long-term culture is possible.
The co-culture may be performed in a CO2 incubator with a CO2 flow amount of 5 to 15% at 35 to 37 r , but the present invention is not particularly limited.
In addition, according to an exemplary embodiment of the present invention, through the stimulation with feeder cells expressing 4-1BBL/CD80/CD83/CD40L or 4-1BBL/CD80/CD83, rather than the stimulation with zoledronic acid, high purity γδ T cells may be obtained, and the differentiation into central memory cells may last longer. Moreover, compared with the stimulation with feeder cells expressing 4-1BBL/CD80/CD83, the stimulation with feeder cells expressing 4-1BBL/CD80/CD83/CD40L enables long-term proliferation of γδ T cells, and thereby high purity γδ T cells may be obtained, and differentiation into central memory cells may last longer.
In addition, in the case of γδ T cells proliferated by the stimulation of feeder cells expressing 4-1BBL/CD80/CD83, an anti-apoptotic molecule is expressed such that cell proliferation is maintained for a long time, and the γδ T cells exhibit apoptotic capacity with respect to tumor cells.
Hereinafter, the present invention will be described in further detail with reference to examples according to the present invention, but the scope of the present invention is not limited by the following examples.
(Cells)
Human samples were reviewed and approved by the Institutional Review Board of Catholic University, Korea. PBMCs were collected according to leukapheresis, and centrifuged using a Ficoll-Paque (GE Healthcare) density gradient. CD4− T cells and CD8+ T cells were isolated using CD4+ T cell and CD8+ T cell isolation kits (Miltenyi Biotec) according to magnetic cell sorting for positive selection (isolated to reach 95% or more purity). γδ T cells were isolated from PBMCs newly purified using an anti-TCRγ/δ MicroBead kit (Miltenyi Biotec) according to magnetic cell sorting (isolated to reach 60% or more purity). Particularly, to isolate Vγ9Vδ2 T cells (isolated to reach 95% or more purity), the γδ T cells were sorted using FACSAria (Becton Dickinson) so as to be further isolated into CD3+ and Vγ9+ subsets.
For cell surface staining, the cells were incubated with anti-TCRVγ9-PE (B3) and anti-CD3-FITC (OKT3) on ice for 30 minutes. A Burkitt's lymphoma cell line Daudi, an erythroid bone marrow cell line K562 and a leukemia cell line U937 were obtained from ATCC, and cultured in a complete medium. The complete medium was a 1640 RPMI (Lonza) medium containing 10% heat-inactivated FBS (Gibco), 2 mM L-glutamine (Lonza), 100 U/mL of penicillin (Lonza), and 100 μg/mL of streptomycin (Lonza).
(Establishment of Feeder Cells)
Human CD80, 4-1BBL and CD83 genes were amplified from cDNA through PCR, and cloned into 3.1-neo (Invitrogen) and a pLXSN retrovirus vector (Clontech). First, K32 was prepared by transducing CD80 into K562 cells. Then, K80/4-1BBL and K80/CD83 were produced by transducing 4-1BBL or CD83 into K80 cells. Finally, K80/4-1BBL/CD83 was produced by transducing CD83 into K80/4-1BBL. Human CD80 and 4-1BBL genes were cloned from a U937 cell line, and the CD83 gene was cloned from mature DC. pcDNA3/CD80 and/or pLXSN/4-1BBL and/or pcDNA3/CD83 plasmids were sequentially transformed into K562 cells using Nucleofector Kit V (Amaxa) according to the manufacturer's instructions. The transformants were cultured in the presence of 1 mg/mL of G-418 DISULPHATE (Duchefa Biochemie). The transformed cells were further selected by FACSAria. All artificial APCs were identified as a mycoplasma-free line, as determined by PCR (data not shown).
(FACS Analysis)
The following mAbs were used to test surface expression of costimulatory molecules and activation markers in K562 and Vγ9Vδ2 T cells: FITC-, PE-, Alexa Fluor 488-, APC-, or Cy5-conjugated mAbs: anti-CD3(OKT3), anti-TCRVδ2(B6), anti-HLA-A,B,C(W6/32), anti-CD27(O323), anti-CD27(0323), anti-CD45RA(HI100), anti-CD32(FUN-2), anti-CD25(BC96), anti-CD69(FN50), anti-CD28(CD28 .2), anti-CD86(IT 2.2), anti-137(4B4-1), anti-137L(5F4), anti-CD 83 (HB 15 e), anti-CD80(2D 10), anti-NKG2D(CD314), anti-TCRVγ9(B3), anti-TCRγ/6(B1), and anti-HLA-DR,DQ-PE Abs.
All antibodies were purchased from BioLegend or Ancell. Simply put, 1×106 viable T cells in 100 pi of PBS (Lonza) were washed twice with 2% FBS-containing PBS. The cells stained with cell surface markers were fixed using 1% paraformaldehyde in PBS. Subsequently, the cells were analyzed using FACSCalibur (Becton Dickinson). Data was analyzed using FlowJo software (Tree Star).
(Expansion of Vγ9Vδ2 T Cells)
The Vγ9Vδ2 T cells used for expansion were prepared by isolating CD3+ and Vγ9+ cells from PBMCs in peripheral blood using FACSAria. Cell culture was performed (2 mL/well) in a 24-well plate (Nunc) containing a complete culture medium supplemented with 20 IU/mL of IL-2 (NOVARTIS). 1×106 Vγ9Vδ2 T cells and 5×105 irradiated (100 Gy) K80/4-1BBL/CD83, K80/4-1BBL or K80/CD83 cells were added to each well. And then, the cells were incubated at 37° C. under a 5% CO2 condition.
The growing Vγ9Vδ2 T cells were harvested every 3 or 4 days, counted, and stimulated again at 7 to 10-day intervals. The Vγ9Vδ2 T cells were plated again at 1 x 106 cells/well in addition to 5 x 105 irradiated artificial APCs, and loaded in a complete culture medium under conditions of 37° C. and 5% CO2.
PBMCs were stimulated with 5 μM zoledronic acid (Novartis) in a complete culture medium consisting of 1640 RPMI (Lonza) containing 10% inactivated FBS. An IL-2 (1000 IU/mL)-containing medium was added every 3 or 4 days, and the culture were transferred to a new 24-well plate under conditions of 37° C. and 5% CO2.
The Vγ9Vδ2 T cells were centrifuged with a Ficoll-Paque density gradient to remove dead Vγ9Vδ2 T cells and remaining artificial APCs, and then cryopreserved in liquid nitrogen until further use.
(ELISA)
Vγ9Vδ2 T cells were stimulated with K80/4-1BBL/CD83, K80/4-1BBL or K80/83, and 20 IU/mL of IL-2-loaded artificial APCs in a complete medium at 37° C. for 72 hours. A supernatant was collected, centrifuged to remove cell debris, and then stored at −20° C. . The concentrations of IL-2, IL-6, IFN-γ, TNF-α, GM-CSF, IL-4, IL-10, TGF-β, and IL-17a in the supernatant were measured through ELISA (BioLegend) according to the manufacturer's instructions.
(Analysis of RNA Expression By Reverse Transcription-PCR)
Vγ9Vδ2 T cells were stimulated with K80/4-1BBL/CD83, K80/4-1BBL or K80/83 and 20 IU/mL of IL-2-loaded artificial APCs in a complete medium at 37° C. for 7 days. The Vγ9Vδ2 T cells were harvested, and total RNA was extracted using an RNeasy Mini kit (QIAGEN). In a reverse transcription reaction, cDNA was synthesized using a Transcriptor First Strand cDNA Synthesis kit (Roche) with a 2.5 μM anchored-oligo (dT) primer and Transcriptor Reverse Transcriptase (Roche), and amplified by PCR using the following primers:
All of the above primers were disclosed previously (DeBarros, A. et al. Eur J Immunol 2011. 41: 195-201; Dokouhaki, P. et al. Cancer Lett 2010. 297: 126-136).
For each specimen, 20 μL of a reaction mixture contained a reaction buffer, 1 mM of each deoxynucleotide mixture, 20U of Protector RNase Inhibitor, 10 pM of each primer, 10U of Transcriptor Reverse Transcriptase. The thermocycling program was as follows: 50° C. for 1 hour and 83° C. for 10 minutes for cDNA amplification. The housekeeping gene GAPDH was used as a reference gene for quantification. The product was isolated from a 1.2% agarose gel at 100 volts for 25 minutes. mRNA was analyzed using Image Lab software (BIO-RAD).
(Cytotoxicity Assay)
A standard 51Cr-release assay was performed, as described in Park, M. Y. et al. Eur J Immunol 2008. 38: 2106-2117. Simply put, K562 and Daudi cell lines were incubated with 100 mCi [51Cr] sodium chromate/1×106 cells under conditions of 37° C. and 5% CO2 for 1 hour. The 51Cr-labeled target cells were incubated with effector cells, i.e., Vγ9Vδ2 T cells, at 37° C. for 4 hours. The supernatant (100 μL) was harvested, and radioactivity was counted using a gamma counter (Packard). The percent specific incorporation was calculated by the formula: [(experimental release-spontaneous release)/(maximum release-spontaneous release)]×100. The spontaneous release and the maximum release were measured in media and in the presence of 2% Triton-X100.
(Statistical Analysis)
All data was analyzed using a statistic program GraphPad Prism 5.0 (GraphPad Software Inc.). The difference between values was evaluated using a Student's t-test. Significance was determined when p<0.05.
As shown in
According to the stimulation process diagram shown in
As shown in
In addition, most of the differentiation markers were identified as effector memory types in 7-day in vitro proliferation after the treatment of four types of human peripheral blood with zoledronic acid and a high concentration of IL-2 for 7 days (
However, after the treatment with zoledronic acid and a high concentration of IL-2 for 7 days, γδ T cells were stimulated using feeder cells and a low concentration of IL-2 (20 IU/mL), and as a result of subsets analysis the γδ T cells, it was confirmed that, unlike γδ T cells stimulated only with zoledronic acid, there was subsets of central memory cells (
After the number of γδ T cells was increased through the treatment with zoledronic acid and IL-2 (1000 IU/mL) for 7 days, 7 days later, the γδ T cells were stimulated using feeder cells and a low concentration of IL-2 (20 IU/mL) without a separate purification process, for example, by using microspheres or through FACS sorting, and then subsets analysis was performed for the γδ T cells proliferated in vitro according to the presence or absence of an immunostimulatory ligand, which is an anti-CD3 antibody (refer to
As shown in
As described above, it was found that the in vitro proliferation of γδ T cells using the stimulation of feeder cells expressing the costimulatory molecules such as CD80, CD83 and 4-1BBL is performed for a long time, differentiation into central memory cells, rather than γδ T cells induced by a phosphoantigen, lasts longer, and high purity γδ T cells were able to be obtained.
Among feeder cells expressing various types of costimulatory molecules, γδ T cells proliferated using feeder cells expressing all of 4-1BBL/CD80/CD83 exhibited the highest proliferation rate, the reason of which was proved by confirming the expression of an apoptosis-inhibiting molecule.
For in vitro proliferation of γδ T cells, feeder cells expressing costimulatory molecules 4-1BBL/CD80/CD83/CD40L, which are an immunostimulatory ligand-free K562 cell line, were established (
Unlike the case using zoledronic acid, when the feeder cells expressing 4-1BBL/CD80/CD83/CD40L were used, it can be seen that, the cells were continuously proliferated over 21 days without a decrease in proliferation rate, and the proliferation rate was about 16.5 fold higher than when feeder cells expressing 4-1BBL/CD80/CD83 were used.
In addition, in the case of the feeder cells expressing 4-1BBL/CD80/CD83/CD40L, the γδ T cells were able to be proliferated when a T cell receptor was not stimulated with anti-CD3.
As described above, it was found that the in vitro proliferation of γδ T cells using the stimulation with the feeder cells expressing 4-1BBL/CD80/CD83/CD40L was able to be performed for a long time, and obtained higher purity γδ T cells than those induced by a phosphoantigen or the stimulation with the feeder cells expressing 4-1BBL/CD80/CD83, and compared to the γδ T cells induced by phosphoantigen stimulation, the differentiation of the γδ T cells proliferated using the feeder cells expressing 4-1BBL/CD80/CD83/CD40L into central memory cells is longer maintained.
The present invention may be applied to the field of adoptive immunotherapy.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2016-0150338 | Nov 2016 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2017/012701 | 11/10/2017 | WO | 00 |
